VBI Vaccines, Inc. - Ordinary Shares (VBIV): Price and Financial Metrics


VBI Vaccines, Inc. - Ordinary Shares (VBIV): $1.69

-0.06 (-3.16%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VBIV to Watchlist
Sign Up

Industry: Biotech


Ranked

of 456

in industry

VBIV POWR Grades


  • VBIV scores best on the Sentiment dimension, with a Sentiment rank ahead of 52.46% of US stocks.
  • VBIV's strongest trending metric is Growth; it's been moving up over the last 163 days.
  • VBIV ranks lowest in Quality; there it ranks in the 1st percentile.

VBIV Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for VBIV is 0 -- better than merely 7.1% of US stocks.
  • VBIV's price/sales ratio is 659.48; that's higher than the P/S ratio of 99.19% of US stocks.
  • As for revenue growth, note that VBIV's revenue has grown -51.46% over the past 12 months; that beats the revenue growth of just 3.67% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to VBI Vaccines Inc are CRMD, XAIR, GEVO, NSTG, and AMWL.
  • VBIV's SEC filings can be seen here. And to visit VBI Vaccines Inc's official web site, go to www.vbivaccines.com.

VBIV Valuation Summary

  • VBIV's price/sales ratio is 1021.2; this is 8897.36% higher than that of the median Healthcare stock.
  • Over the past 243 months, VBIV's price/sales ratio has gone down 1426.5.
  • Over the past 243 months, VBIV's price/sales ratio has gone down 1426.5.

Below are key valuation metrics over time for VBIV.

Stock Date P/S P/B P/E EV/EBIT
VBIV 2021-08-31 1021.2 5.5 -14.6 -13.8
VBIV 2021-08-30 1004.2 5.4 -14.3 -13.5
VBIV 2021-08-27 1012.7 5.5 -14.4 -13.6
VBIV 2021-08-26 959.0 5.2 -13.7 -12.8
VBIV 2021-08-25 913.7 4.9 -13.0 -12.1
VBIV 2021-08-24 891.0 4.8 -12.7 -11.8

VBIV Growth Metrics

    Its 5 year net income to common stockholders growth rate is now at -109.29%.
  • Its 5 year price growth rate is now at -75.92%.
  • Its 2 year net cashflow from operations growth rate is now at -33.5%.
Over the past 43 months, VBIV's revenue has gone down $202,000.

The table below shows VBIV's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 0.714 -37.887 -66.332
2021-06-30 0.905 -48.957 -63.482
2021-03-31 0.947 -46.046 -55.519
2020-12-31 1.061 -47.05 -46.23
2020-09-30 1.471 -39.085 -41.743
2020-06-30 1.82 -37.863 -44.908

VBIV's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VBIV has a Quality Grade of F, ranking ahead of 2.02% of graded US stocks.
  • VBIV's asset turnover comes in at 0.004 -- ranking 418th of 681 Pharmaceutical Products stocks.
  • NOVN, CKPT, and ARWR are the stocks whose asset turnover ratios are most correlated with VBIV.

The table below shows VBIV's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.004 -9.583 -1.419
2021-03-31 0.005 -8.508 -1.124
2020-12-31 0.006 -7.641 -1.240
2020-09-30 0.010 -5.345 -1.736
2020-06-30 0.014 -4.054 -3.663
2020-03-31 0.019 -3.171 -175.420

VBIV Stock Price Chart Interactive Chart >

Price chart for VBIV

VBIV Price/Volume Stats

Current price $1.69 52-week high $4.83
Prev. close $1.74 52-week low $1.55
Day low $1.65 Volume 1,447,874
Day high $1.74 Avg. volume 2,756,654
50-day MA $2.42 Dividend yield N/A
200-day MA $2.99 Market Cap 433.56M

VBI Vaccines, Inc. - Ordinary Shares (VBIV) Company Bio


VBI Vaccines Inc. develops vaccine candidates and novel technology platforms in Israel and internationally. It develops products based on eVLP, a platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccines platform, a proprietary formulation and process that allows vaccines and biologics to preserve stability, potency, and safety. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.


VBIV Latest News Stream


Event/Time News Detail
Loading, please wait...

VBIV Latest Social Stream


Loading social stream, please wait...

View Full VBIV Social Stream

Latest VBIV News From Around the Web

Below are the latest news stories about VBI Vaccines Inc that investors may wish to consider to help them evaluate VBIV as an investment opportunity.

Pan-COVID-19 Vaccine Could Be a Solution to End the Pandemic; Jefferies Taps 2 Stocks to Benefit

The coronavirus pandemic is still making headlines; it’s presenting us with a stubborn problem, one that won’t go away and resists the normal weapons that modern medicine has brought against it. The result is a sense of fatalism, that we may as well just get used to corona. No one likes that idea. The medical researchers, especially, aren’t liking that, and they are working to bring new techniques to bear on the virus. Among the more promising is the ‘pan-COVID’ approach, the development of a va

Yahoo | January 20, 2022

VBI Vaccines Announces Dosing of First Patient in Second Phase 2 Study in Chronic Hepatitis B Patients as Part of Expansion of Clinical Collaboration With Brii Bio

CAMBRIDGE, Mass., January 05, 2022--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the first patient has been dosed in a second Phase 2a/2b clinical study evaluating VBI-2601 (BRII-179), an immunotherapeutic candidate targeting chronic hepatitis B virus (HBV). This newly announced Phase 2 study will assess VBI-2601 as an add-on therapy to the standard-of-care, nucleos(t)

Yahoo | January 5, 2022

VBI Vaccines a buy at Jefferies on vaccine technology platform; sees 171% upside

Jefferies has assumed coverage of VBI Vaccines (VBIV +0.2%) with a buy rating on the company's "versatile" vaccine technology platform. The firm has a $6 price target on shares (~171% upside based on yesterday's close). Analyst Roger Song says that VBI's platform can provide several large market opportunities. He adds...

Seeking Alpha | December 29, 2021

These 2 “Strong Buy” Penny Stocks Are Poised to Take Off, Says Raymond James

Let’s talk about penny stocks. These are equities that trade for less than $5 per share, the very bottom of the price range. While they are priced that low for a reason – and the reasons may vary – low price in itself doesn’t mean that the stock’s fundamentals are sour. Smart investors can find some true bargains among the penny stocks, and set themselves up for outsized gains.

Michael Marcus on TipRanks | December 29, 2021

VBI Vaccines Announces Filing of New Drug Submission for 3-Antigen Hepatitis B Vaccine to Health Canada

CAMBRIDGE, Mass., December 09, 2021--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the filing of a New Drug Submission (NDS) to Health Canada for the Company’s 3-antigen prophylactic hepatitis B vaccine candidate, seeking approval in Canada for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults.

Yahoo | December 9, 2021

Read More 'VBIV' Stories Here

VBIV Price Returns

1-mo N/A
3-mo -41.32%
6-mo -42.91%
1-year -47.84%
3-year 3.05%
5-year -55.41%
YTD -27.78%
2021 -14.91%
2020 99.28%
2019 -13.75%
2018 -62.53%
2017 37.74%

Continue Researching VBIV

Here are a few links from around the web to help you further your research on VBI Vaccines Inc's stock as an investment opportunity:

VBI Vaccines Inc (VBIV) Stock Price | Nasdaq
VBI Vaccines Inc (VBIV) Stock Quote, History and News - Yahoo Finance
VBI Vaccines Inc (VBIV) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9008 seconds.